Autolus Therapeutics plc (AUTL) — SEC Financial Statements & Analysis

Autolus Therapeutics plc (AUTL) is a biological products, (no diagnostic substances) company, incorporated in X0. Autolus Therapeutics plc trades on Nasdaq as: AUTL. Autolus Therapeutics plc (AUTL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Autolus Therapeutics plc carries a market cap of $425.85M, a P/E ratio of -1.52x, a P/B ratio of 5.69x, a P/S ratio of 3.63x, an enterprise value of $252.94M, and an EV/EBITDA multiple of -1.06x. On profitability, it posts a gross margin of 184.34%, an operating margin of -210.78%, a net margin of -238.66%, a Return on Equity (ROE) of -133.00%, a Return on Assets (ROA) of -46.15%, and a Return on Invested Capital (ROIC) of -194.94%. Per share, it reports EPS of $-1.05, diluted EPS of $-1.05, free cash flow per share of $-0.88, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 292.16% year-over-year, net income growth of 23.00% year-over-year, and EPS growth of 22.99% year-over-year. On the balance sheet, it maintains a current ratio of 4.89x, a quick ratio of 3.60x, working capital of $267.30M, a debt-to-equity ratio of 5.59x, a debt ratio of 0.85, an interest coverage ratio of -5.25x, free cash flow of $-234.50M (TTM), and net debt of $-172.91M. Figures sourced from SEC EDGAR.

Market Cap

$425.85M

P/E TTM

-1.52x

EPS TTM

$-1.05

P/B TTM

5.69x

ROE TTM

-133.00%

ROA TTM

-46.15%

Debt To Equity

5.59x

Free Cash Flow TTM

$-234.50M

Net Revenue TTM Growth 1Y

292.16%

Data as of 2026-06-30 · Source: SEC EDGAR